ARVINAS, INC.
Close on Oct 19, 2026
- Market cap
- $476.98M
- P/E (TTM)
- 45.4
- Dividend yield
- –
About Arvinas
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology business that develops targeted therapies using a proprietary proteolysis targeting chimera protein degradation platform. Its technology directs the body's natural protein disposal mechanisms to break down and remove disease-causing proteins. Operating across oncology and neurology therapeutic areas, the company's clinical pipeline includes vepdegestrant for advanced breast cancer, ARV-102 for neurodegenerative disorders, ARV-806 for solid tumors, ARV-393 for non-Hodgkin lymphoma, and ARV-027. The firm also maintains research collaborations with pharmaceutical partners such as Pfizer and Genentech. Its target end-users are patients suffering from severe oncologic and neurological conditions.
The provided text does not state the location of the company's headquarters. Regarding operational scale, seven drug programs generated from its discovery platform have advanced into clinical trials, alongside several preclinical candidates and research programs. In terms of geographic reach, the text references regulatory submissions and clinical activities in the United States, as well as clinical trial application clearance in the Netherlands.
Summary of the business section of Arvinas's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ARVINAS, INC.
- Founded
- 2013
- Headquarters
- New Haven, CT
- Address
- 395 Winchester Ave, 5 Science Park 06511
- Phone
- (203) 535-1456
- Website
- arvinas.com
- Employees
- 246, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ARVN
- Exchange
- Nasdaq
- IPO date
- Sep 27, 2018
- Shares outstanding
- 65M, Jul 31, 2026
- Public float
- $469.00M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1655759
- CUSIP
- 04335A105
- ISIN
- US04335A1051
- EIN
- 47-2566120
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Randy Teel | President and CEO, Director | 285,009 |
| Andrew Saik | Chief Financial Officer | 187,432 |
| Angela M. Cacace | Chief Scientific Officer | 180,390 |
| Noah Berkowitz | Chief Medical Officer | 191,395 |
| David K. Loomis | VP, Chief Accounting Officer | 40,193 |
| Ian Taylor | President, R&D | 160,785 |
| Briggs Morrison | Director | 111,548 |
| Linda Bain | Director | 41,572 |
| Leslie V. Norwalk | Director | 41,572 |
| Edward Moore Kennedy Jr. | Director | 84,290 |
| Alsup Laurie Smaldone | Director | 41,572 |
| Everett Cunningham | Director | 41,572 |
| John G. Houston | Director | 1,122,183 |
| Sunil Agarwal | Director | 30,166 |
| John D. Young | Director | 26,045 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 John Houston, Ph.D. | $6.53M | $2.58M | $2.79M | $14 | $125 |
| FY2024 John Houston, Ph.D. | $12.75M | $3.23M | $3.42M | $23 | $93 |
| FY2023 John Houston, Ph.D. | $7.63M | $5.98M | $2.73M | $48 | $94 |
| FY2022 John Houston, Ph.D. | $9.55M | $6.68M | $3.52M | $40 | $90 |
| FY2021 John Houston, Ph.D. | $12.60M | $9.30M | $4.26M | $97 | $100 |
| FY2020 John Houston, Ph.D., | $8.02M | $26.46M | $2.89M | $207 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 246 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 28, 2018 | Name change | Name changed from ARVINAS HOLDING COMPANY, LLC to ARVINAS INC. |
| Sep 27, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 21, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |